These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 27490030)

  • 21. Non-nucleoside inhibitors of NS5B polymerase binding to allosteric sites: 3D- QSAR and molecular docking studies.
    Cao H; Cao R; Zhang H; Zheng X; Gao D
    Curr Med Chem; 2008; 15(15):1462-77. PubMed ID: 18537623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase.
    Shih IH; Vliegen I; Peng B; Yang H; Hebner C; Paeshuyse J; Pürstinger G; Fenaux M; Tian Y; Mabery E; Qi X; Bahador G; Paulson M; Lehman LS; Bondy S; Tse W; Reiser H; Lee WA; Schmitz U; Neyts J; Zhong W
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4196-203. PubMed ID: 21746939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigation of the mode of binding of a novel series of N-benzyl-4-heteroaryl-1-(phenylsulfonyl)piperazine-2-carboxamides to the hepatitis C virus polymerase.
    Gentles RG; Sheriff S; Beno BR; Wan C; Kish K; Ding M; Zheng X; Chupak L; Poss MA; Witmer MR; Morin P; Wang YK; Rigat K; Lemm J; Voss S; Liu M; Pelosi L; Roberts SB; Gao M; Kadow JF
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2212-5. PubMed ID: 21441029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding mode determination of benzimidazole inhibitors of the hepatitis C virus RNA polymerase by a structure and dynamics strategy.
    LaPlante SR; Jakalian A; Aubry N; Bousquet Y; Ferland JM; Gillard J; Lefebvre S; Poirier M; Tsantrizos YS; Kukolj G; Beaulieu PL
    Angew Chem Int Ed Engl; 2004 Aug; 43(33):4306-11. PubMed ID: 15368379
    [No Abstract]   [Full Text] [Related]  

  • 25. Dynamics of hepatitis C virus (HCV) RNA-dependent RNA polymerase NS5B in complex with RNA.
    Karam P; Powdrill MH; Liu HW; Vasquez C; Mah W; Bernatchez J; Götte M; Cosa G
    J Biol Chem; 2014 May; 289(20):14399-411. PubMed ID: 24692556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening and molecular docking of selected phytochemicals against NS5B polymerase of hepatitis c virus.
    Mustafa G; Majid M; Ghaffar A; Yameen M; Samad HA; Mahrosh HS
    Pak J Pharm Sci; 2020 Sep; 33(5(Supplementary)):2317-2322. PubMed ID: 33832906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The versatile nature of the 6-aminoquinolone scaffold: identification of submicromolar hepatitis C virus NS5B inhibitors.
    Manfroni G; Cannalire R; Barreca ML; Kaushik-Basu N; Leyssen P; Winquist J; Iraci N; Manvar D; Paeshuyse J; Guhamazumder R; Basu A; Sabatini S; Tabarrini O; Danielson UH; Neyts J; Cecchetti V
    J Med Chem; 2014 Mar; 57(5):1952-63. PubMed ID: 24131104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127).
    LaPlante SR; Bös M; Brochu C; Chabot C; Coulombe R; Gillard JR; Jakalian A; Poirier M; Rancourt J; Stammers T; Thavonekham B; Beaulieu PL; Kukolj G; Tsantrizos YS
    J Med Chem; 2014 Mar; 57(5):1845-54. PubMed ID: 24159919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of anthranilic acid derivatives as a novel class of allosteric inhibitors of hepatitis C NS5B polymerase.
    Nittoli T; Curran K; Insaf S; DiGrandi M; Orlowski M; Chopra R; Agarwal A; Howe AY; Prashad A; Floyd MB; Johnson B; Sutherland A; Wheless K; Feld B; O'Connell J; Mansour TS; Bloom J
    J Med Chem; 2007 May; 50(9):2108-16. PubMed ID: 17402724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular dynamics and docking reveal the potency of novel GTP derivatives against RNA dependent RNA polymerase of genotype 4a HCV.
    Elfiky AA; Ismail A
    Life Sci; 2019 Dec; 238():116958. PubMed ID: 31628915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quinolones as HCV NS5B polymerase inhibitors.
    Kumar DV; Rai R; Brameld KA; Somoza JR; Rajagopalan R; Janc JW; Xia YM; Ton TL; Shaghafi MB; Hu H; Lehoux I; To N; Young WB; Green MJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):82-7. PubMed ID: 21145235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of novel Hepatitis C virus inhibitor targeting multiple allosteric sites of NS5B polymerase.
    Khalid H; Landry KB; Ijaz B; Ashfaq UA; Ahmed M; Kanwal A; Froeyen M; Mirza MU
    Infect Genet Evol; 2020 Oct; 84():104371. PubMed ID: 32485331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ligand-induced changes in hepatitis C virus NS5B polymerase structure.
    Rigat K; Wang Y; Hudyma TW; Ding M; Zheng X; Gentles RG; Beno BR; Gao M; Roberts SB
    Antiviral Res; 2010 Nov; 88(2):197-206. PubMed ID: 20813137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation.
    Ryu K; Kim ND; Choi SI; Han CK; Yoon JH; No KT; Kim KH; Seong BL
    Bioorg Med Chem; 2009 Apr; 17(8):2975-82. PubMed ID: 19332375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anthranilic acid-based Thumb Pocket 2 HCV NS5B polymerase inhibitors with sub-micromolar potency in the cell-based replicon assay.
    Stammers TA; Coulombe R; Duplessis M; Fazal G; Gagnon A; Garneau M; Goulet S; Jakalian A; LaPlante S; Rancourt J; Thavonekham B; Wernic D; Kukolj G; Beaulieu PL
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6879-85. PubMed ID: 24176401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tri-substituted acylhydrazines as tertiary amide bioisosteres: HCV NS5B polymerase inhibitors.
    Canales E; Carlson JS; Appleby T; Fenaux M; Lee J; Tian Y; Tirunagari N; Wong M; Watkins WJ
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4288-92. PubMed ID: 22664130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of novel natural flavonoids as potent antiviral candidates against hepatitis C virus NS5B polymerase.
    Akher FB; Farrokhzadeh A; Ramharack P; Shunmugam L; Van Heerden FR; Soliman MES
    Med Hypotheses; 2019 Nov; 132():109359. PubMed ID: 31466018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
    Herlihy KJ; Graham JP; Kumpf R; Patick AK; Duggal R; Shi ST
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3523-31. PubMed ID: 18694956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resolution of the interaction mechanisms and characteristics of non-nucleoside inhibitors of hepatitis C virus polymerase.
    Winquist J; Abdurakhmanov E; Baraznenok V; Henderson I; Vrang L; Danielson UH
    Antiviral Res; 2013 Mar; 97(3):356-68. PubMed ID: 23305851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of inhibition for BMS-791325, a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase.
    Rigat KL; Lu H; Wang YK; Argyrou A; Fanslau C; Beno B; Wang Y; Marcinkeviciene J; Ding M; Gentles RG; Gao M; Abell LM; Roberts SB
    J Biol Chem; 2014 Nov; 289(48):33456-68. PubMed ID: 25301950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.